Encorafenib vs HLX208
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: BRAF V600E · full Non-Small Cell Lung Cancer pipeline
Encorafenib
Marketed by Pfizer and partners
NCT03915951 · Phase 2 · completed
The study was open-label, single-group, and had no placebo or active comparator, so the objective response results cannot be directly attributed to the treatment relative to another therapy. Its primary radiographic response endpoint was reported separately for 59 treatment-naive and 39 previously treated participants, but there was no formal between-group primary comparison.
Reported efficacy
Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8) (not_applicable)
Result source: NCT03915951
HLX208
Developed by Shanghai Henlius Biotech and partners
NCT05065398 · Phase 2 · status unknown
This is a small, open-label, single-arm study with no control group, so there is no formal comparison to test HLX208's benefit against, and it enrolls only about 20 patients. No results have been posted yet.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Encorafenib | HLX208 |
|---|---|---|
| PFS, median | —Not reported | —Not reported |
| OS, median | —Not reported | —Not reported |
| ORR | 74.6%bNCT039159513 other results
| —Not reported |
| Duration of response, median | —Not reported | —Not reported |
PFS, median
- Encorafenib
- —Not reported
- HLX208
- —Not reported
OS, median
- Encorafenib
- —Not reported
- HLX208
- —Not reported
ORR
- Encorafenib
- 74.6%bNCT03915951
3 other results
- 46.2% NCT03915951
- 62.7% NCT03915951
- 41% NCT03915951
- HLX208
- —Not reported
Duration of response, median
- Encorafenib
- —Not reported
- HLX208
- —Not reported
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HLX208: no structured comparison results are available for Non-Small Cell Lung Cancer.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Encorafenib: 3 of 4 rows · HLX208: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Encorafenib |
|---|---|
| Dropout rate | n/a: no completion milestonePreviously Treateda NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 2 more resultsn/a: no completion milestoneTreatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 n/a: no completion milestone NCT05003622 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 15.4%Previously Treateda NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 2 more results20.3%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 — NCT05003622 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 43.6%Previously Treateda NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 2 more results42.4%Treatment-Naive NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 66.7% NCT05003622 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 51.3% nausea 48.7% fatigue 41% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 show 2 more resultsnausea 62.7% diarrhoea 49.2% fatigue 49.2% NCT03915951 · Phase 2 · combination · Non-Small Cell Lung Cancer · phase 2 neutrophil count increased 100% proteinuria 100% constipation 66.7% NCT05003622 · Phase 1 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 1 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Encorafenib
show 3 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Encorafenib's landscape · HLX208's landscape